<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658409</url>
  </required_header>
  <id_info>
    <org_study_id>GC3106_AD_P3</org_study_id>
    <nct_id>NCT02658409</nct_id>
  </id_info>
  <brief_title>A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study to Investigate the Efficacy (Immunogenicity) and Safety of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase
      III Study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase
      III Study to Investigate the Efficacy (Immunogenicity) and Safety of GC3106 (quadrivalent
      cell-culture based influenza vaccine) after Intramuscular Administration in Healthy Subjects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of the vaccination after 21 days of hemagglutination inhibition antibody (HI antibody) titer was measured through the GMT ratio</measure>
    <time_frame>Day 21 post vaccination</time_frame>
    <description>(GMT control drug/ GMT test drug)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of the vaccination after 21 days of hemagglutination inhibition antibody (HI antibody) titer was measured through the difference between the SCRs</measure>
    <time_frame>Day 21 post vaccination</time_frame>
    <description>(SCR control drug- SPR test drug)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited adverse events: Day 0~Day 6</measure>
    <time_frame>Day 0~Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse events: Day 0~Day 21</measure>
    <time_frame>Day 0~Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of subjects achieving seroconversion, defined as post vaccination HI antibody titers</measure>
    <time_frame>21 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of subjects achieving seroprotection, defined as post vaccination HI antibody titers</measure>
    <time_frame>21 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign and physical examination</measure>
    <time_frame>For 180 days after Visit 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For 180 days after Visit 1, serious adverse events were presented with the results.</measure>
    <time_frame>For 180 days after Visit 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1630</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GC3106(quadrivalent)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, intramuscular, a single dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix™tetra Syringe Inj.(Quadrivalent)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5ml,intramuscular,a single dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC3106(quadrivalent cell-culture based influenza vaccine)</intervention_name>
    <description>GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1</description>
    <arm_group_label>GC3106(quadrivalent)</arm_group_label>
    <other_name>GC3106</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)</intervention_name>
    <description>Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1</description>
    <arm_group_label>Fluarix™tetra Syringe Inj.(Quadrivalent)</arm_group_label>
    <other_name>Fluarix™tetra Syringe Inj.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Given written informed consent

          -  Healthy Korean adults (age: between over 19)

          -  Women of childbearing age with negative Urine hCG in screening visit

        Exclusion Criteria:

          -  Subjects unable to communicate (illiterate or who cannot understand the questionnaire
             and/or the study subject diary)

          -  Subjects participating in another clinical study or has participated in a clinical
             study in the last 30 days (the participation should be based on the final dose of the
             investigational drug)

          -  Subjects with impaired immune functions that include immune deficiency diseases

          -  Subjects with a history of Guillain-Barre syndrome

          -  Hemophilia patients at risk of serious bleeding with intramuscular injection or who
             had taken an anticoagulant

          -  Subjects with symptoms of active infection or who had higher than 38.0℃ fever before
             the investigational product administration

          -  Subjects to be planned to have a surgery in the study duration or subject who the
             investigator decides exception because of a clinical significant chronic or malignant
             disease or medical history to interrupt the study procedure

          -  Subjects with erythema and/or a tattoo in the injection site of the scheduled
             investigational product (the deltoid muscle) that is hard to identify the topical
             toxicity

          -  Subjects with a history of allergic reaction to eggs or chicken, the vaccine
             components, and/or Formaldehyed, Gentamicin and Sodium Deoxychloate

          -  Subjects who had been administered the influenza vaccine 6 months before the scheduled
             vaccination of the investigational product

          -  Subjects who had been vaccinated with another vaccine within 30 days before the
             investigational product administration or had a scheduled vaccination during the
             clinical study period

          -  Subjects who had received an immunosuppressant, immunity-modifying drug, cytotoxic
             chemotherapy that can affect his or her immune system, or radiation therapy within 3
             months before the investigational product administration

          -  Subjects receiving systemic steroids (more than 20 mg/day of prednisolone administered
             everyday over 14 days or more than 700 mg of a cumulative dose during the same period
             of time) within 3 months before the administration (Day 1) of the investigational
             product (topical ointments, eye drops, inhalants or intranasally/intramuscularly
             administered drugs, or topically applied drugs such as ligaments; unless administered
             every other day over 14 days)

          -  Subjects who had received immunoglobulin or a blood-derived product within 3 months
             before being vaccinated with the investigational product or is scheduled to receive
             those products during the clinical study period

          -  Pregnant women, nursing mothers, or women of childbearing age who do not perform
             adequate contraception (using a condom, diaphragm, IUD, or hormonal contraception 21
             days before vaccination with the investigational product or whose male partner had
             undergone a vasectomy)

        Subjects who have other clinically significant medical or psychiatric examination findings
        deemed by the investigator to make them ineligible for participation in this clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Jin Su, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Choi Won Seck, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Ja Cob</last_name>
    <role>Study Director</role>
    <affiliation>Hallym Univ. Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Heong Jung</last_name>
    <role>Study Director</role>
    <affiliation>Hallym Univ. Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wi Sung Heon</last_name>
    <role>Study Director</role>
    <affiliation>St. Vincent's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeong Suk In</last_name>
    <role>Study Director</role>
    <affiliation>Chonnam Natinal University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Sin Woo</last_name>
    <role>Study Director</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Tae Hyung</last_name>
    <role>Study Director</role>
    <affiliation>Soon Chun Hyang Univ. Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CCIV</keyword>
  <keyword>quadrivalent cell-culture based influenza vaccine</keyword>
  <keyword>Influenza vaccine</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

